Skip to contentV
Voyager Therapeutics, Inc.
V
VYGRVoyager Therapeutics, Inc. Q3 2018 · 10-Q
Revenue$2.09M$2.09M+82.4% vs Q3 2017 Net Income-$20.29M-$20.29MN/M vs Q3 2017 EPS Diluted-$0.63-$0.63N/M vs Q3 2017 Operating Income-$21,147,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Voyager Therapeutics, Inc. · CIK 1640266 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$18,496,000N/M Margins · derivedOperating margin-1009.9%+1024.5 pt vs Q3 2017
Net margin-968.9%+1064.7 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 7, 2018 · 38 d after period end